Organovo (ONVO) Competitors $1.72 +0.06 (+3.61%) As of 04/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONVO vs. NRSN, CLDI, SLGL, MEIP, COCP, SYBX, IPA, QNTM, MTVA, and IMNNShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include NeuroSense Therapeutics (NRSN), Calidi Biotherapeutics (CLDI), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Cocrystal Pharma (COCP), Synlogic (SYBX), ImmunoPrecise Antibodies (IPA), Quantum Biopharma (QNTM), MetaVia (MTVA), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. Organovo vs. NeuroSense Therapeutics Calidi Biotherapeutics Sol-Gel Technologies MEI Pharma Cocrystal Pharma Synlogic ImmunoPrecise Antibodies Quantum Biopharma MetaVia Imunon NeuroSense Therapeutics (NASDAQ:NRSN) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the MarketBeat Community favor NRSN or ONVO? Organovo received 194 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 45.79% of users gave Organovo an outperform vote. CompanyUnderperformOutperformNeuroSense TherapeuticsOutperform Votes266.67% Underperform Votes133.33% OrganovoOutperform Votes19645.79% Underperform Votes23254.21% Which has better earnings & valuation, NRSN or ONVO? NeuroSense Therapeutics has higher earnings, but lower revenue than Organovo. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$11.28M-$0.54-1.91Organovo$122K23.98-$14.67M-$10.20-0.17 Is NRSN or ONVO more profitable? NeuroSense Therapeutics has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. NeuroSense Therapeutics' return on equity of 0.00% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -590.79% Organovo -10,151.64%-346.26%-187.53% Which has more volatility & risk, NRSN or ONVO? NeuroSense Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Does the media refer more to NRSN or ONVO? In the previous week, Organovo had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Organovo and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of -0.07 beat Organovo's score of -0.50 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Overall Sentiment NeuroSense Therapeutics Neutral Organovo Negative Do analysts rate NRSN or ONVO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of NRSN or ONVO? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryNeuroSense Therapeutics beats Organovo on 10 of the 15 factors compared between the two stocks. Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONVO vs. The Competition Export to ExcelMetricOrganovoBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.93M$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-2.0230.4821.8617.80Price / Sales23.98441.91380.5497.75Price / CashN/A168.6838.2634.64Price / Book86.003.466.453.98Net Income-$14.67M-$72.06M$3.22B$247.81M7 Day Performance3.61%2.54%2.85%1.80%1 Month Performance-64.51%-15.71%-8.67%-6.81%1 Year Performance-87.54%-26.11%11.46%1.31% Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONVOOrganovo0.3547 of 5 stars$1.72+3.6%N/A-87.2%$2.93M$122,000.00-2.0220Short Interest ↑NRSNNeuroSense Therapeutics0.4648 of 5 stars$0.97-2.0%N/A-35.4%$13.26MN/A-1.5210Short Interest ↑CLDICalidi Biotherapeutics2.1198 of 5 stars$0.50flat$15.00+2,923.6%N/A$13.13M$50,000.000.0038Gap UpSLGLSol-Gel Technologies1.9948 of 5 stars$0.47+0.9%$5.00+963.8%-35.8%$13.09M$11.71M-1.3850News CoverageGap UpMEIPMEI Pharma2.2442 of 5 stars$1.93-3.5%$7.00+262.7%-41.0%$12.86M$65.30M-0.34100Analyst ForecastShort Interest ↓COCPCocrystal Pharma1.9948 of 5 stars$1.26-11.3%$7.00+455.6%-8.0%$12.82MN/A-0.6810Gap DownSYBXSynlogicN/A$1.08flatN/A-40.1%$12.63M$8,000.00-0.2680IPAImmunoPrecise Antibodies2.7068 of 5 stars$0.40+12.3%$4.00+889.6%-65.5%$12.56M$24.00M-0.5280Short Interest ↓Gap DownQNTMQuantum BiopharmaN/A$6.36-10.0%N/AN/A$12.21MN/A-0.41N/AGap DownMTVAMetaVia2.0474 of 5 stars$1.40-4.0%$12.00+756.5%N/A$12.13MN/A0.0010Analyst ForecastNews CoverageGap DownHigh Trading VolumeIMNNImunon1.6381 of 5 stars$0.83-13.9%$21.50+2,501.3%-21.9%$12.08M$500,000.00-0.4430Short Interest ↑Negative News Related Companies and Tools Related Companies NeuroSense Therapeutics Competitors Calidi Biotherapeutics Competitors Sol-Gel Technologies Competitors MEI Pharma Competitors Cocrystal Pharma Competitors Synlogic Competitors ImmunoPrecise Antibodies Competitors Quantum Biopharma Competitors MetaVia Competitors Imunon Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONVO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONVO Stock Free ONVO Stock Alerts